RxDoctor Payments Data

Rose Marie Zmyslinski, APRN

Psychiatric/Mental Health · New London, CTNPI 1750460770

Payments from drug & device makers

$527in general payments, 2019–2025

Across 36 payments — averaging $14.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$220
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$145
  • Neurocrine Biosciences, Inc.$73
  • Otsuka America Pharmaceutical, Inc.$44
  • Alkermes, Inc.$20
  • Supernus Pharmaceuticals, Inc.$13
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$48191%
  • Education$479%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$527 in reported general payments places this provider in the 55th percentile of 679 psychiatric/mental health providers in Connecticut.

See all psychiatric/mental health providers in Connecticut

Medicare billing

Part B allowed, 2024
$17,464
Medicare patients
57
Services billed
200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate94$281,887
Abilify MaintenaAripiprazole37$88,645
AustedoDeutetrabenazine15$59,461
RexultiBrexpiprazole16$27,406
Risperidone ErRisperidone Microspheres22$23,644
AristadaAripiprazole Lauroxil11$21,275
Aripiprazole203$15,402
SaphrisAsenapine Maleate12$14,814
Tetrabenazine13$7,709
Paliperidone ErPaliperidone62$6,869
Clozapine125$6,820
Lurasidone Hcl41$6,617
Vilazodone Hcl32$4,519
Tiagabine Hcl13$3,477
Bupropion XlBupropion Hcl166$3,036

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$44$116,05153 claims
Alkermes, Inc.Aristada$20$21,27511 claims
AbbVieSaphris$220$14,81412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 679 psychiatric/mental health providers in Connecticut.

Other psychiatric/mental health in New London

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →